Evidence map›Paper›PMID 41822747›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2026

Investigation of antimicrobial synergism of actinomycin derivatives from

Özge Can, Mustafa Ünver Kurt, Melis Küçüksolak, Ataç Uzel, Erdal Bedir

Abstract read
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Özge CanDepartment of Bioengineering, Faculty of Engineering, Izmir Institute of Technology, İzmir, Turkiye.ORCID https://orcid.org/0000-0002-3203-645X
Mustafa Ünver KurtDepartment of Bioengineering, Faculty of Engineering, Izmir Institute of Technology, İzmir, Turkiye.ORCID https://orcid.org/0000-0001-5702-8168
Melis KüçüksolakDepartment of Bioengineering, Faculty of Engineering, Izmir Institute of Technology, İzmir, Turkiye.ORCID https://orcid.org/0000-0003-1619-4850
Ataç UzelDepartment of Biology, Faculty of Science, Ege University, İzmir, Turkiye.ORCID https://orcid.org/0000-0002-1304-0509
Erdal BedirDepartment of Bioengineering, Faculty of Engineering, Izmir Institute of Technology, İzmir, Turkiye.ORCID https://orcid.org/0000-0003-1262-063X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Limited drug development and increased antibiotic tolerance among Gram-negative bacteria have led researchers to consider combination therapy. Actinomycin derivatives, particularly actinomycin D, exhibit a wide range of bioactivities, including antibacterial effects. However, actinomycin D is less effective against Gram-negative pathogens. Therefore, it is essential to demonstrate the synergy of actinomycin D and its derivatives with clinically known antibiotics against Materials and methods: Results: Individual actinomycins exhibited weak antimicrobial activity (MICs > 100 μM). Nevertheless, strong synergistic effects were actinomycins D and X Conclusion: This work represents the first multimodel synergy analysis of actinomycin analogs against

Indexed as

Actinomycetesdactinomycindrug synergismEscherichia coli

Identifiers

PMID41822747
PMCPMC12978764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.